Regression analysis of ordinal stroke clinical trial outcomes: an application to the NINDS t-PA trial

Int J Stroke. 2014 Feb;9(2):226-31. doi: 10.1111/ijs.12052. Epub 2013 Jun 27.

Abstract

Background: The modified Rankin scale (mRS) is the most common functional outcome assessed in stroke trials. The proportional odds model is commonly used to analyze this ordinal outcome but it requires a restrictive assumption that a single odds ratio applies across the entire outcome scale.

Aims: The study aims to model the effect of tissue-type plasminogen activator on ordinal mRS, test model assumptions, and compare fits and predictive ability of the statistical models.

Methods: Several ordinal regression methods are presented and applied to a re-analysis of the 1995 NINDS tissue-type plasminogen activator study. Violations of the proportional odds assumption are demonstrated using graphs and statistical tests, and the partial proportional odds model is introduced and recommended as an alternative for the analysis of mRS.

Results: The partial proportional odds model relaxes the assumptions about treatment effect on the ordinal outcome scale and provides a better fit to the data than the commonly used proportional odds model (likelihood ratio test chi-square = 8·05, P = 0·005). It provides easily interpretable odds ratios and it is able to detect efficacy at the lower end and a lack of efficacy at the upper end of the mRS scale. Further, it provides lower prediction error than the proportional odds model (0·002 versus 0·005).

Conclusions: Assuming proportional odds when it does not hold can mask differential treatment effects at the upper end of the ordinal mRS scale and has implications for reduced power when studies are designed under this assumption.

Keywords: clinical trial; modified Rankin scale; ordinal regression; partial proportional odds; proportional odds; tissue plasminogen activator.

MeSH terms

  • Clinical Trials as Topic / standards*
  • Humans
  • National Institute of Neurological Disorders and Stroke (U.S.) / standards*
  • Odds Ratio
  • Regression Analysis
  • Stroke / drug therapy*
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome*
  • United States

Substances

  • Tissue Plasminogen Activator